Equities analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will post earnings per share of ($0.60) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.67). Heron Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which would indicate a positive year over year growth rate of 4.8%. The firm is scheduled to report its next earnings results on Monday, August 3rd.

According to Zacks, analysts expect that Heron Therapeutics will report full year earnings of ($2.33) per share for the current year, with EPS estimates ranging from ($2.77) to ($1.41). For the next year, analysts anticipate that the company will post earnings of ($0.92) per share, with EPS estimates ranging from ($2.00) to $0.19. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.08. Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. The company had revenue of $25.40 million for the quarter, compared to analysts’ expectations of $21.23 million. During the same quarter in the previous year, the company posted ($0.80) EPS. The business’s revenue was down 19.6% compared to the same quarter last year.

HRTX has been the subject of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $44.00 target price on shares of Heron Therapeutics in a research note on Wednesday, April 15th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Tuesday, May 12th. BidaskClub cut shares of Heron Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 14th. Stifel Nicolaus reiterated a “buy” rating and issued a $29.00 target price on shares of Heron Therapeutics in a research note on Wednesday, May 6th. Finally, ValuEngine cut shares of Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and an average target price of $40.63.

NASDAQ HRTX traded up $0.70 during trading on Friday, reaching $15.12. The company’s stock had a trading volume of 744,921 shares, compared to its average volume of 1,281,861. The company has a current ratio of 4.53, a quick ratio of 4.17 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $1.32 billion, a PE ratio of -6.66 and a beta of 1.51. The business has a 50-day moving average price of $13.80 and a 200-day moving average price of $19.52. Heron Therapeutics has a 1-year low of $9.60 and a 1-year high of $26.81.

A number of large investors have recently added to or reduced their stakes in HRTX. Franklin Resources Inc. raised its stake in Heron Therapeutics by 19.6% during the 4th quarter. Franklin Resources Inc. now owns 12,361,411 shares of the biotechnology company’s stock valued at $290,496,000 after purchasing an additional 2,026,380 shares during the last quarter. Norges Bank acquired a new position in Heron Therapeutics during the 4th quarter valued at $23,384,000. Farallon Capital Management LLC acquired a new position in Heron Therapeutics during the 4th quarter valued at $20,563,000. Goldman Sachs Group Inc. raised its stake in Heron Therapeutics by 122.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,537,619 shares of the biotechnology company’s stock valued at $36,134,000 after purchasing an additional 847,578 shares during the last quarter. Finally, State Street Corp raised its stake in Heron Therapeutics by 24.4% during the 4th quarter. State Street Corp now owns 3,376,057 shares of the biotechnology company’s stock valued at $79,337,000 after purchasing an additional 663,063 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: What causes a recession?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.